The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -223,123 |
| Depreciation and amortization of property and equipment | 8,871 |
| Amortization of finance lease right of use asset | 2,154 |
| Impairment of operating lease right-of-use asset | 262 |
| Stock-based compensation | 37,059 |
| Accretion of discount on investments, net | 6,974 |
| Change in fair value of warrant liabilities | 0 |
| Prepaid expenses and other assets | -2,089 |
| Accounts payable and accrued expenses | -10,351 |
| Operating lease liabilities and right of use assets, net | 45 |
| Finance lease liability | 35 |
| Other liabilities | -81 |
| Net cash used in operating activities | -190,014 |
| Purchases of investments | 276,553 |
| Proceeds from maturities of investments | 380,760 |
| Purchases of property and equipment | 440 |
| Net cash provided by investing activities | 103,767 |
| Issuance of common stock, net of issuance costs-Public Offering | 0 |
| Issuance of common stock pursuant to exercise of stock options | 0 |
| Return of related party short-swing profits | 215 |
| Repurchase of restricted stock units to satisfy tax withholding | 67 |
| Net cash provided by financing activities | 148 |
| Net change in cash, cash equivalents and restricted cash | -86,099 |
| Cash, cash equivalents and restricted cash at beginning of period | 164,997 |
| Cash, cash equivalents and restricted cash at end of period | 78,898 |
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)